Drug Trial Radar · NCT06596876
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Nov 6, 2024
Primary completion
Jan 29, 2026
Study completion Jan 29, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.
Conditions
- Parkinson's Disease
Interventions
HRG2010; Sustained-release Carbidopa/Levodopa administered placeboDrug
Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
Sustained-release Carbidopa/Levodopa; HRG2010 placeboDrug
Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in "Off" time at Week 21Time frame: Last three days collected at the end of treatment period, at Week 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.